

Sarcopenia as a Predictor of Survival in Patients with Pancreatic Cancer After Pancreatectomy

Annals of Surgical Oncology

29, 1553-1563

DOI: [10.1245/s10434-021-10995-y](https://doi.org/10.1245/s10434-021-10995-y)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant chemotherapy timing. <i>Cancer Medicine</i> , 2022, 11, 3397-3406.	1.3	3
2	Prognostic value of computed tomography derived skeletal muscle mass index in lung cancer: A meta-analysis. <i>World Journal of Clinical Cases</i> , 2022, 10, 6927-6935.	0.3	1
3	Combined assessment of muscle quality and quantity predicts oncological outcome in patients with esophageal cancer. <i>American Journal of Surgery</i> , 2023, 225, 1036-1044.	0.9	3
4	Sarcopenia in pancreatic cancer: Effect on patient outcomes. <i>World Journal of Gastrointestinal Oncology</i> , 0, 14, 2302-2312.	0.8	4
5	Sarcopenia is an Independent Prognostic Factor in Patients With Pancreatic Cancer – a Meta-analysis. <i>Academic Radiology</i> , 2023, 30, 1552-1561.	1.3	5
6	Sarcopenia of kidney transplant recipients as a predictive marker for reduced graft function and graft survival after kidney transplantation. <i>Langenbeck's Archives of Surgery</i> , 2023, 408, .	0.8	1